Adenocarcinoma: all 1,996 studies

Page 4 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal AdenocarcinomaRecruitingNCT05248750
• Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo MeasurementsRecruitingNCT05247346Not applicable
• Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic AdenocarcinomaRecruitingNCT05241249Phase 2
• Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric AdenocarcinomaRecruitingNCT05237349Phase 2
• A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
• SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaNot yet recruitingNCT05218148Phase 2
• TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerRecruitingNCT05188313Phase 3
• Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction AdenocarcinomaRecruitingNCT05184946Phase 2
• Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)RecruitingNCT05177133Phase 2
• Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction AdenocarcinomaRecruitingNCT05170503Phase 2
• Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric CancerRecruitingNCT05163483Phase 2
• Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingNCT05132985Phase 2
• Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric AdenocarcinomaRecruitingNCT05122091Phase 2
• Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative FistulaRecruitingNCT05116072Phase 1/2
• Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic AdenocarcinomaRecruitingNCT05083247Phase 2
• Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT04999332Phase 2
• Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic AdenocarcinomaRecruitingNCT04998552Not applicable
• Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaRecruitingNCT04997837Phase 3
• S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction AdenocarcinomaRecruitingNCT04989985Phase 2
• Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic CancerRecruitingNCT04969731Phase 3
• Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
• Peritoneal Lavage Liquid Biopsy in Patients With Gastric CancerRecruitingNCT04943406
• Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric JunctionRecruitingNCT04910789Not applicable
• Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04908566Phase 2
• Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance StrategyEnrolling by invitationNCT04875325Not applicable
• Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.RecruitingNCT04850729
• A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach AdenocarcinomaRecruitingNCT04799548Phase 2
• Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic CancerEnrolling by invitationNCT04793633
• Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerRecruitingNCT04781686Phase 2
• Evaluation of the Reliability of the Determination of MisMatch Repair Deficiency Status by Endoscopic Biopsies in Oesophagus and Gastric Adenocarcinoma.Not yet recruitingNCT04774367Not applicable
• Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)Enrolling by invitationNCT04755517Not applicable
• Prospective Prostate Cancer and Patient-reported Outcomes RegistryRecruitingNCT04694924
• Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT04660760Phase 2
• Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the PancreasRecruitingNCT04617457Phase 2
• RPSA as a Potential Prognostic Biomarker of Pancreatic CancerRecruitingNCT04575363Not applicable
• Jump: MR Simulation For Radiation Therapy Master ProtocolRecruitingNCT04545957Not applicable
• PAXG Out in the CountryRecruitingNCT04480268Phase 4
• Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before SurgeryRecruitingNCT04452461Phase 2
• HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)RecruitingNCT04447352Phase 3
• FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT04393584Phase 2/3
• SERum-bank for PANcreatic CancerRecruitingNCT04374175
• Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel ChemotherapiesRecruitingNCT04361708Phase 1
• Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic AdenocarcinomaRecruitingNCT04303403Phase 1
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
• RAMPS VS SRPS for Pancreatic Body and Tail AdenocarcinomaNot yet recruitingNCT04253847Not applicable
• Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility StudyRecruitingNCT04219137
• FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOXRecruitingNCT04167007Phase 3
• Clinical Outcomes of Robotic Versus Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III AEGEnrolling by invitationNCT04153058Not applicable
• PACAREG: a Multicenter Registry Trial in Pancreatic Ductal AdencarcinomaRecruitingNCT04099134
• Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric AdenocarcinomaRecruitingNCT04047953Not applicable
• Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal CancerRecruitingNCT04018872Phase 2
• Risk of GAstric Adenocarcinoma After Cephalic DuodenopancreatectomyRecruitingNCT03991065Not applicable
• Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric AdenocarcinomaRecruitingNCT03973008Phase 3
• Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ AdenocarcinomaNot yet recruitingNCT03961841Phase 3
• Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy SystemsRecruitingNCT03961776
• Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 ResectionRecruitingNCT03817268Phase 3
• Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized RiskRecruitingNCT03417336Not applicable
• Adjuvant Chemotherapy for High Risk Stage I Lung AdenocarcinomaRecruitingNCT03380468Phase 2/3
• Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%RecruitingNCT03351842Phase 2
• Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal AdenocarcinomaRecruitingNCT03222635Not applicable
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
• D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric AdenocarcinomaNot yet recruitingNCT03051152Not applicable
• PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided RadiotherapyRecruitingNCT02973828
• Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and OverRecruitingNCT02355379Phase 3
• Beyond TME OriginsRecruitingNCT02292641Not applicable
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingNCT02133196Phase 2
• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by invitationNCT00923026
• Novel Serum Markers for Monitoring Response to Anti-Cancer TherapyRecruitingNCT00349830
• Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresEnrolling by invitationNCT00102544Not applicable
• Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2TerminatedNCT05980416Phase 1Results posted
• A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)TerminatedNCT05577715Phase 2Results posted
• A Trial of NIS793 With FOLFIRINOX in Pancreatic CancerTerminatedNCT05546411Phase 2Results posted
• A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)TerminatedNCT05311176Phase 2Results posted
• Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results posted
• Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results posted
• Milademetan in Advanced/Metastatic Solid TumorsTerminatedNCT05012397Phase 2Results posted
• Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior RegimensCompletedNCT04989816Phase 2Results posted
• Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminatedNCT04951492Phase 2Results posted
• RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results posted
• Evaluation of PSMA Antagonist Produced by Two Different MethodsCompletedNCT04685811Phase 1/2Results posted
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract TumorsTerminatedNCT04683939Phase 1/2Results posted
• Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyCompletedNCT04646005Phase 2Results posted
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/2Results posted
• Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal AdenocarcinomaTerminatedNCT04565327Phase 2Results posted
• MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent CetuximabCompletedNCT04554836Phase 2Results posted
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results posted
• PROState Pathway Embedded Comparative TrialCompletedNCT04400656Results posted
• A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerTerminatedNCT04363801Phase 2Results posted
• Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT04329949Phase 3Results posted
• Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT04292743Phase 1Results posted
• Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction AdenocarcinomaTerminatedNCT04260191Phase 1Results posted
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
• Trial of NanoPac Focal Therapy for Prostate CancerTerminatedNCT04221828Phase 2Results posted
• Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.TerminatedNCT04171141Phase 1Results posted
• Pre-operative Adaptive Short Court Radiation Therapy in Gastric CancerTerminatedNCT04162665Phase 2Results posted
• Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerActive, not recruitingNCT04117945Phase 2Results posted
• Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) AdenocarcinomaCompletedNCT04097028Phase 2Results posted
• Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal AdenocarcinomaTerminatedNCT04089904Phase 2Results posted
• TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04074343Phase 1Results posted
• Comparative Health Research Outcomes of NOvel Surgery in Prostate CancerCompletedNCT04049747Not applicableResults posted

← Adenocarcinoma overview